S17 Ep51: RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD
About this episode
Gerald Soff, MD discusses the RECITE trial findings on romiplostim for managing chemotherapy-induced thrombocytopenia in GI cancer patients.
Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty. OncLive On Air is a podcast from OncLive® , which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In this episode of OncLive On Air, Gerald Soff, MD, sat down with OncLive to discuss findings from the phase 3 RECITE trial (NCT03362177), which evaluated romiplostim for the management of chemotherapy-induced thrombocytopenia (CIT) in patients with gastrointestinal cancers. Soff is a professor of clinical medicine in the Division of Hematology and chief of the Classical Hematology Section at the University of Miami Miller School of Medicine in Florida. During the interview, Soff reviewed the longstanding unmet need for effective CIT management and explained how thrombopoietin receptor agonists, such as romiplostim, may help maintain platelet counts and preserve chemotherapy delivery; highlighted key findings from RECITE; and discussed the concept of relative dose intensity and why maintaining…
More episodes of OncLive® On Air
- S17 Ep59: ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions
- S17 Ep58: DLBCL 2026 UPDATE
- S17 Ep57: Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC
- S17 Ep56: Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS
- S17 Ep55: Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis
- S17 Ep54: Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology
Explore listener stats, chart rankings, contacts and more on the OncLive® On Air podcast page.